Boyu Cap­i­tal helps point Cel­gene-part­nered An­ten­gene down a quick path to com­mer­cial­iza­tion

Shang­hai-based An­ten­gene has ush­ered in the first biotech mega-round of the year, de­signed to fu­el a quick com­mer­cial turn­around of in-li­censed can­cer drugs.

The $120 mil­lion Se­ries B marks a sig­nif­i­cant boost for the young biotech, which was found­ed in April 2017 on a deal with Cel­gene $CELG, and quite pos­si­bly the last fi­nanc­ing round be­fore An­ten­gene heads to an IPO — ac­cord­ing to pre­vi­ous com­ments by CEO Jay Mei.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER